BP102
Phase 2Small molecule
Shanghai Hengrui Pharmaceutical Co., Ltd.BP102 is one of 108 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.
4
Indications
6
Total Trials
4
Active Trials
107
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
268 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Trifluridine/tipiracil
AbbViePhase 3
Telisotuzumab Adizutecan
AbbViePhase 3
Botensilimab
AAgenus Inc.
Phase 3
XL092
RochePhase 3
Zanzalintinib
Merck & Co.Phase 3
Calcium Folinate
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Iron Isomaltoside
TThomas Jefferson University
Phase 3
Tucidinostat
CChipscreen Biosciences, Ltd.
Phase 3
Clostridium Butyricum
XXijing Hospital of Digestive Diseases
Phase 3
Mfolfoxiri
DDominik Paul Modest
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer2 trials
Malignant Solid Tumors1 trial
Colorectal Cancer1 trial
Non-squamous NSCLC1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BP102. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details